ReviewInternational journal of molecular sciences2015
Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Effects of Agomelatine on Sleep Across Populations: A Systematic Review and Meta-Analysis.Journal of sleep research · 2026Pooled it
- Pharmacological Treatments for Disordered Gambling: A Meta-analysis.Journal of gambling studies · 2019Pooled it
- The effect of acupuncture on depression and its correlation with metabolic alterations: A randomized controlled trial.Medicine · 2020Trial
- Cytoprotective Effects of Agomelatine on Hepatic Ischemia-Reperfusion Injury in a Rat Model.International journal of molecular sciences · 2026Article
- Rectal In Situ Thermosensitive Gel Loaded with Agomelatine-Silver Nanoparticles: Formulation and Characterization.Gels (Basel, Switzerland) · 2026Article
- Seizures Temporally Associated With SSRI Treatment: A Two-Case Report Exploring Agomelatine as a Treatment Alternative.Case reports in psychiatry · 2026Article
- The integrative role of melatonin in psychiatric disorders: A systematic review of evidence from circadian biology, lifestyle medicine, and psychoneuroimmunology.BioMedicine · 2025Review
- Review
- The Use of Melatoninergic Antidepressants for Stabilization of Remission in Depression Comorbid with Alcohol Abuse, Anxiety or Neuropsychiatric Disorders: A Systematic Review.Consortium psychiatricum · 2024Review
- Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.Brain sciences · 2023Review
- The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Agomelatine Changed the Expression and Methylation Status of Inflammatory Genes in Blood and Brain Structures of Male Wistar Rats after Chronic Mild Stress Procedure.International journal of molecular sciences · 2022Article
- Sleep Problems in Chronic Inflammatory Diseases: Prevalence, Treatment, and New Perspectives: A Narrative Review.Journal of clinical medicine · 2021Review
- Targeting Epigenetic Mechanisms to Treat Alcohol Use Disorders (AUD).Current pharmaceutical design · 2021Article
- Article
- GW117: A novel serotonin (5-HTCNS neuroscience & therapeutics · 2021Article
- Agomelatine prevents macrophage infiltration and brain endothelial cell damage in a stroke mouse model.Aging · 2021Article
- Molecular Regulation of the Melatonin Biosynthesis Pathway in Unipolar and Bipolar Depression.Frontiers in pharmacology · 2021Article
- 17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats.Psychopharmacology · 2020Article
- Agomelatine Attenuates Isoflurane-Induced Inflammation and Damage in Brain Endothelial Cells.Drug design, development and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agomelatine, a melatonergic antidepressant with a rapid onset of action, is one of the most recent drugs in the antidepressant category. Agomelatine's antidepressant actions are attributed to its sleep-promoting and chronobiotic actions mediated by MT1 and MT2 receptors present in the suprachiasmatic nucleus, as well as to its effects on the blockade of 5-HT2c receptors. Blockade of 5-HT2c receptors causes release of both noradrenaline and dopamine at the fronto-cortical dopaminergic and noradrenergic pathways. The combined actions of agomelatine on MT1/MT2 and 5-HT2c receptors facilitate the resynchronization of altered circadian rhythms and abnormal sleep patterns. Agomelatine appeared to be effective in treating major depression. Moreover, evidence exists that points out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Thus, the aim of this narrative review was to elucidate current evidences on the role of agomelatine in disorders other than major depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.